NACHC Hopes Congress Will Pass Laws Protecting 340B Providers This Year

NACHC “would love to see” Congress pass legislation by the end of this year protecting health centers from drug manufacturers and PBMs' restrictions on 340B access, NACHC Senior Vice President Joe Dunn said during a news conference yesterday.

The National Association of Community Health Centers “would love to see” Congress pass legislation by the end of this year that stops drug makers from restricting 340B contract pharmacy arrangements and stops pharmacy benefit managers from taking covered

Read More »

News Alert

25 States File Joint Briefs Backing HHS and HRSA in 340B Contract Pharmacy Cases

Connecticut Attorney General William Tong (D) led the coalition of states backing the federal government in 340B contract pharmacy cases before federal appeals courts.

Twenty-five states are backing the federal government in litigation before two federal appeals courts over drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies.

Please Login or Become a Paid Subscriber

Read More »

340B Providers Lose their Biggest GOP Ally in U.S. House

U.S. Rep. David McKinley (R-W.Va.) lost his GOP primary election this week. It's a huge blow for 340B entities that have relied on his help in Congress for years.

In a major blow to the 340B provider community, U.S. Rep. David McKinley, the leading voice for the 340B program in the House Republican caucus, was defeated Tuesday in the West Virginia Republican primary. McKinley will remain in

Read More »

Six Groups Slam Drug Makers’ 340B Pricing Conditions on Hepatitis C Medicines

Six HIV/AIDS and viral hepatitis advocacy groups issued a joint statement criticizing AbbVie, Gilead, and Merck’s conditions on 340B pricing on hepatitis C medications.

Six groups that support patients with HIV/AIDS and viral hepatitis and their caregivers issued a joint statement yesterday criticizing drug manufacturers AbbVie, Gilead, and Merck’s conditions on 340B pricing on hepatitis C medications.

Please

Read More »

48 Hospitals Seek Readmission to 340B After Losing Eligibility Due to COVID-19 Pandemic

Forty eight hospitals that lost their eligibility for 340B drug discounts for reasons related to the COVID-19 pandemic are seeking reinstatement to the 340B program.

At least 48 hospitals lost their eligibility for 340B drug discounts for reasons related to the COVID-19 pandemic and are seeking reinstatement to the 340B program, HRSA says.

Please Login or Become a Paid

Read More »

340B Hospitals’ Pharmacies and Child Sites Often Located in Richer, Less Diverse Areas, Study Finds

Avalere Health says it found that 340B DSH hospitals’ contract pharmacies and child sites often are in richer and less diverse places where more residents have health insurance compared with the hospitals’ own locations.

Many National Cancer Institute (NCI) designated cancer centers—most of which are affiliated with 340B hospitals—mark up the price of infused cancer therapies for patients with private insurance “substantially,” according to new research in JAMA Internal Medicine.

Read More »

JAMA Study Finds Prominent Cancer Centers With 340B Connections Mark Up Infused Drugs Significantly

New research in JAMA Internal Medicine says many NCI-designated cancer centers—most of which are affiliated with 340B hospitals—mark up the price of infused cancer therapies for patients with private insurance “substantially." 340B groups point out that the rates are negotiated and they need the revenue for their safety net mission.

Many National Cancer Institute (NCI) designated cancer centers—most of which are affiliated with 340B hospitals—mark up the price of infused cancer therapies for patients with private insurance “substantially,” according to new research in JAMA Internal Medicine.

Read More »

Harvard Drug Policy Experts Write in JAMA About How Congress Could Fix 340B Contract Pharmacy Mess

"Contract pharmacy restrictions are the latest problem with implementation of the 340B program that threaten to undermine its laudable goals," three Harvard drug policy experts say in an opinion article in JAMA.

A nationally prominent drug policy expert and two colleagues at Harvard Medical School have written in JAMA how Congress could end the fight over 340B contract pharmacy and enhance 340B program integrity.

Please Login

Read More »

At Direction of U.S. Appeals Court, Judge Issues Amended Judgement in Lilly’s 340B Contract Pharmacy Case

It is unknown whether U.S. Senior District Judge Sarah Evans Barker’s amended partial final judgement in Lilly's 340B contract pharmacy lawsuit will satisfy a higher court that kicked the case back to her.

A federal district judge in Indianapolis last week responded to a higher court’s directive and entered an amended partial final judgement in drug manufacturer Lilly’s 340B contract pharmacy lawsuit.

Please Login or Become a Paid Subscriber

Read More »

Sanofi Makes Two Big Changes to its 340B Contract Pharmacy Policy

Sanofi made two changes to its conditions on 340B pricing when health centers and certain hospitals use contract pharmacies.

Drug manufacturer Sanofi has made two major changes to its conditions on 340B pricing when health centers and certain hospitals and use contract pharmacies, a company spokesperson confirms.

Please Login or Become a Paid Subscriber to

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report